ARDX

Rosen Law Firm is reminding investors who purchased Ardelyx common stock between January 13, 2025 and August 6, 2026 of an important November 16, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Ardelyx provided misleading statements about its commercial performance and concealed material facts regarding reimbursement barriers and access issues affecting its drugs XPHOZAH and IBSRELA.

A securities class action has been filed against Ardelyx, Inc. (NASDAQ: ARDX) alleging the company misled investors about its commercial performance and growth prospects for its drug products IBSRELA and XPHOZAH. The lawsuit covers purchases between January 13, 2025 and August 6, 2026. On August 6, 2026, Ardelyx reduced its full-year 2026 IBSRELA revenue guidance and withdrew long-term XPHOZAH guidance due to increased payer access barriers, causing the stock to drop 18% in one day from $4.87 to $4.00 per share.

Schall, Brown & Schwartz LLP has filed a class action lawsuit against Ardelyx, Inc. for alleged securities violations. The lawsuit claims the company made false and misleading statements regarding reimbursement barriers and patient access issues for its drugs XPHOZAH and IBSRELA, which impacted commercial performance. The class period spans January 13, 2025 to August 6, 2026, with a deadline of November 16, 2026 for shareholders to participate.